The L‐α‐Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background and Aims: G protein–coupled receptor (GPR) 55 is a putative cannabinoid receptor, and l‐α‐lysophosphatidylinositol (LPI) is its only known endogenous ligand. Although GPR55 has been linked to energy homeostasis in different organs, its specific role in lipid metabolism in the liver and its contribution to the pathophysiology of nonalcoholic fatty liver disease (NAFLD) remains unknown. Approach and Results: We measured (1) GPR55 expression in the liver of patients with NAFLD compared with individuals without obesity and without liver disease, as well as animal models with steatosis and nonalcoholic steatohepatitis (NASH), and (2) the effects of LPI and genetic disruption of GPR55 in mice, human hepatocytes, and human hepatic stellate cells. Notably, we found that circulating LPI and liver expression of GPR55 were up‐regulated in patients with NASH. LPI induced adenosine monophosphate–activated protein kinase activation of acetyl–coenzyme A carboxylase (ACC) and increased lipid content in human hepatocytes and in the liver of treated mice by inducing de novo lipogenesis and decreasing β‐oxidation. The inhibition of GPR55 and ACCα blocked the effects of LPI, and the in vivo knockdown of GPR55 was sufficient to improve liver damage in mice fed a high‐fat diet and in mice fed a methionine‐choline–deficient diet. Finally, LPI promoted the initiation of hepatic stellate cell activation by stimulating GPR55 and activation of ACC. Conclusions: The LPI/GPR55 system plays a role in the development of NAFLD and NASH by activating ACC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“Some types of circulating lysophospholipids have emerged as signaling molecules with important effects on inflammation and fatty liver disease.(32-34) In line with this, our present results indicate that LPI levels are increased in patients with NASH.”
ResultActivation of the peripheral endocannabinoid system in human obesity
Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2838 · Cited by 686 · cited 1×
“Pathologic overactivation of the ECS is associated with the development of dyslipidemia, obesity, and type 2 diabetes.(4,28,29) These actions of the ECS have been mainly attributed to the activation of central and peripheral CB1 receptors.”
BackgroundMitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease
Begriche, K., Massart, J., Robin, M.-A., Bonnet, F., & Fromenty, B. (2013) · Hepatology · doi:10.1002/hep.26226 · Cited by 628
Savage, D. B. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27300 · Cited by 447 · cited 1×
“Preclinical studies have demonstrated that the lack or inhibition of ACCα and ACCβ reduced steatosis.(25,41-44) Clinical trials showed that GS-0976, an inhibitor of ACC, also reduced hepatic steatosis and fibrosis markers in patients with NASH.”
BackgroundThe role of TGFβ1 in initiating hepatic stellate cell activation in vivo
Hellerbrand, C., Stefanovic, B., Giordano, F., Burchardt, E. R., & Brenner, D. A. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80010-5 · Cited by 393
Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.027 · Cited by 340 · cited 17×
“We found that circulating LPI and liver GPR55 expression levels were increased in patients and animal models with NAFLD.”
BackgroundMethodInfluentialChoi, C. S., Savage, D. B., Abu-Elheiga, L., Liu, Z.-X., Kim, S., Kulkarni, A., Distefano, A., Hwang, Y.-J., Reznick, R. M., Codella, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706794104 · Cited by 325 · cited 1×
“Preclinical studies have demonstrated that the lack or inhibition of ACCα and ACCβ reduced steatosis.(25,41-44) Clinical trials showed that GS-0976, an inhibitor of ACC, also reduced hepatic steatosis and fibrosis markers in patients with NASH.”
BackgroundLawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.042 · Cited by 217
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
Self-citationPathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Lee, K.-C., Wu, P.-S., & Lin, H.-C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 246
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
Metadata
- Authors
- Fondevila, M. F., Fernandez, U., Gonzalez‐Rellan, M. J., Da Silva Lima, N., Buque, X., Gonzalez‐Rodriguez, A., Alonso, C., Iruarrizaga‐Lejarreta, M., Delgado, T. C., Varela‐Rey, M., Senra, A., Garcia‐Outeiral, V., Novoa, E., Iglesias, C., Porteiro, B., Beiroa, D., Folgueira, C., Tojo, M., Torres, J. L., Hernández‐Cosido, L., Blanco, Ó., Arab, J. P., Barrera, F., Guallar, D., Fidalgo, M., López, M., Dieguez, C., Marcos, M., Martinez‐Chantar, M. L., Arrese, M., Garcia‐Monzon, C., Mato, J. M., Aspichueta, P., & Nogueiras, R.
- Venue
- Hepatology
- Published
- 2020-11-13
- Volume
- 73
- Issue
- 2
- Pages
- 606-624
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3018283902
- Cited by
- 62
- References
- 8
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.